IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1803-1808

  Mosca, Deborah A ^a,b   Hurst, Malinda A ^a   So, Wendy ^a   Viajar, Beverly S C ^a   Fujii, Craig A ^a   Falla, Timothy J ^a  

^a IntraBiotics Pharmaceuticals Inc   (United States)

^b Elitra Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; GENTAMICIN; IB 367; NORFLOXACIN; POLYMYXIN B; PROTEGRIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUTH FLORA; MUCOSA INFLAMMATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; SALIVA; STREPTOCOCCUS MITIS; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; MOUTH DISEASES; MOUTH MUCOSA; PEPTIDES; PROTEINS; SALIVA; STREPTOCOCCUS;

EID: 0033948397     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1803-1808.2000     Document Type: Article

References (27)

1. Bansil, R., E. Stanley, and J. T. LaMont. 1995. Mucin biophysics. Annu. Rev. Physiol. 57:635-657.
2. Barker, G. J., S. K. Call, and A. S. Gamis. 1995. Oral care with vancomycin paste for reduction in incidence of hemolytic streptococcal sepsis. J. Pediatr. Hematol. Oncol. 17:151-155.
3. Bergmann, O. J. 1988. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J. Clin. Microbiol. 26:2105-2109.
4. Bochud, P.-Y., P. Eggiman, T. Calandra, G. Van Melle, L. Saghafi, and P. Francioli. 1993. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin. Infect. Dis. 18:25-31.
5. Carl, W. 1995. Oral complications of local and systemic cancer treatment. Curr. Opin. Oncol. 7:320-324.
6. Donnelly, J. P., P. Muus, A. M. Horrevorts, R. W. Sauerwein, and B. E. De Pauw. 1993. Failure of clindamycin to influence the course of severe oromucositis with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scand. J. Infect. Dis. 25:43-50.
7. Epstein, J. B., L. Vickars, J. Spinelli, and D. Recce. 1992. Efficacy of chlorohexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg. Oral Med. Oral Pathol. 73:682-689.
8. Ferretti, G. A., R. C. Ash, A. T. Brown, M. D. Parr, E. H. Romond, and T. T. Lillich. 1988. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorohexidine digluconate oral rinse. Bone Marrow Transplant. 3:483-493.
9. Ferretti, G. A., A. T. Brown, T. P. Raybould, and T. T. Lillich. 1990. Oral antimicrobial agents - chlorhexidine, p. 51-55. NCI monograph 9. Oral complications of cancer. National Cancer Institute, Bethesda, Md.
10. Foote, R. L., C. L. Loprinzi, A. R. Frank, J. R. O'Fallon, S. Gulavita, H. H. Tewfik, M. A. Ryan, J. M. Earle, and P. Novotny. 1994. Randomized trial of a chlorohexidine mouthwash for alleviation of radiation-induced mucositis. J. Clin. Oncol. 12:2630-2633.
11. Greenberg, M. S., S. G. Cohen, J. C. McKitrick, and P. A. Cassileth. 1982. The oral flora as a source of septicemia in patients with acute leukemia. Oral Surg. 53:32-36.
12. Liljemark, W. F., and C. G. Bloomquist. 1994. Normal microbial flora of the human body, p. 120-128. In R. J. Nisengard and M. G. Newman (ed.), Oral microbiology and immunology. The W. B. Saunders Co., Philadelphia. Pa.
13. Loesche, W. J. 1994. Ecology of the oral flora, p. 307-315. In R. J. Nisengard and M. G. Newman (ed.), Oral microbiology and immunology. The W. B. Saunders Co., Philadelphia, Pa.
14. Mueller, B. A., E. T. Millheim, E. A. Farrington, C. Brusko, and T. H. Wiser. 1995. Mucositis management practices for hospitalized patients: national survey results. J. Pain Symptom Manage. 10:510-520.
15. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Schenkels, L. C. P. M., E. C. I. Veerman, and A. V. N. Amerongen. 1995. Biochemical composition of human saliva in relation to other mucosal fluids. Crit. Rev. Oral Biol. Med. 6:161-175.
17. Schubert, M. M., B. E. Williams, M. E. Lloid, G. Donaldson, and M. K. Chapko. 1991. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Cancer 69:469-477.
18. Sonis, S. T. 1993. Oral complications of cancer therapy, p. 2385-2394. In V. DeVita et al. (ed.), Principles and practice of oncology. J. B. Lippincott. Philadelphia, Pa.
19. Spijkervet, F. K. L., H. K. F. van Saene, A. K. Panders, and A. Vermey. 1989. Colonisation index of the oral cavity: a novel technique for monitoring colonisation defence. Microb. Ecol. Health Dis. 2:145-151.
20. Spijkervet, F. K. L., J. J. Saene, H. K. Saene, A. K. Panders, A. Vermey, and V. Fidler. 1990. Chlorohexidine inactivation by saliva. Oral Surg. Oral Med. Oral Pathol. 69:437-443.
21. Spijkervet, F. K. L. 1991b. Oral flora changes in head and neck cancer patients, p. 43-50. In Irradiation mucositis. Munksgaard Press, Copenhagen. Denmark.
22. Spijkervet, F. K. L., H. K. F. van Saene, J. J. M. van Saene, A. K. Panders, A. Vermey, D. M. Mehta, and V. Fidler. 1991. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J. Surg. Oncol. 46:167-173.
23. Steinberg, D. A., M. A. Hurst, C. A. Fujii, A. H. Kung, J. F. Ho, F.-C. Cheng, D. J. Loury, and J. C. Fiddes. 1997. Protegrin-1: a broad spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob. Agents Chemother. 41:1738-1742.
24. Symonds, R. P., P, McIlroy, J. Khorrami, J. Paul, E. Pyper, S. R. Alcock, I. McCallum, A. B. J. Speekenbrink, A. McMurray, E. Lindemann, and M. Thomas. 1996. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br. J. Cancer 74:312-317.
25. van Saene, H. K., and M. V. Martin. 1990. Do microorganisms play a role in irradiation mucositis? Eur. J. Clin. Microbiol. Infect. Dis. 9:861-863.
26. Verdi, C. J. 1993. Cancer therapy and oral mucositis; an appraisal of drug prophylaxis. Drug Safety 9:185-195.
27. Weisdorf, D. J., B. Bostrom, D. Raether, M. Mattingly, P. Walker, B. Pihlstrom, P. Ferrieri, R. Haake, A. Goldman, W. Woods, et al. 1989. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of Chlorohexidine mouth rinse. Bone Marrow Transplant. 4:89-95.